{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:55:55Z","timestamp":1793094955396,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.diagmicrobio.2011.08.006","type":"journal-article","created":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T08:20:15Z","timestamp":1316506815000},"page":"370-377","source":"Crossref","is-referenced-by-count":46,"title":["In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing"],"prefix":"10.1016","volume":"71","author":[{"given":"Shivaprakash M.","family":"Rudramurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunaloke","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Geertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques F.","family":"Meis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12281-008-0006-2","article-title":"Antifungal drug resistance in moulds: clinical and microbiological factors","volume":"2","author":"Alcazar-Fuoli","year":"2008","journal-title":"Curr. Fungal Infect Rep."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0010","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Susceptibility patterns of Aspergillus isolates recovered from patients enrolled in the transplant associated infection surveillance network (TRANSNET)","volume":"47","author":"Baddley","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0015","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/JCM.01070-09","article-title":"Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Balajee","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0020","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01282-10","article-title":"In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus","volume":"55","author":"Calvo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000066764","article-title":"Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P","volume":"48","author":"Carrillo-Munoz","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0030","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.01543-08","article-title":"Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds","volume":"53","author":"Cuenca-Estrella","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0035","series-title":"Atlas of clinical fungi CD ROM","author":"De Hoog","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0040","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jac\/dkn076","article-title":"Activity of BAL 4815 against filamentous fungi","volume":"61","author":"De La Escalera","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0045","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1128\/JCM.02423-06","article-title":"Comparison of two highly discriminatory molecular fingerprinting assays for analysis of multiple Aspergillus fumigatus isolates from patients with invasive aspergillosis","volume":"45","author":"De Valk","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J. Infect."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0060","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi","volume":"41","author":"Diekema","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/JCM.39.3.954-958.2001","article-title":"In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi","volume":"39","author":"Espinel-Ingroff","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/JCM.41.1.403-409.2003","article-title":"Evaluation of broth microdilution testing parameters and agar diffusion E-test procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991)","volume":"41","author":"Espinel-Ingroff","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0075","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1128\/JCM.40.9.3204-3208.2002","article-title":"Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study","volume":"40","author":"Espinel-Ingroff","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0080","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/JB.94.4.928-933.1967","article-title":"Experimental study of the pathogenicity of aspergilli for mice","volume":"94","author":"Ford","year":"1967","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0085","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL 4815), voriconazole, and fluconazole against 1,007 isolate of Zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0090","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/mic.0.2007\/007641-0","article-title":"Aspergillus flavus: human pathogen, allergen and mycotoxin producer","volume":"153","author":"Hedayati","year":"2007","journal-title":"Microbiology"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0095","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0100","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organization for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0105","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0110","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/jac\/dkq041","article-title":"Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands","volume":"65","author":"Klaassen","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl. 3","key":"10.1016\/j.diagmicrobio.2011.08.006_bb0115","first-page":"19","article-title":"Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology","volume":"44","author":"Lass-Fl\u00f6rl","year":"2006","journal-title":"Med. Mycol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0120","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.00662-08","article-title":"Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"52","author":"Lass-Fl\u00f6rl","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0924-8579(02)00189-9","article-title":"Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method","volume":"21","author":"Lass-Fl\u00f6rl","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.diagmicrobio.2005.01.001","article-title":"Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli","volume":"52","author":"Lionakis","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0135","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2011.08.006_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13693780400020113","article-title":"Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program","volume":"43","author":"Morgan","year":"2005","journal-title":"Med. Mycol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0145","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.42.10.2726","article-title":"In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp","volume":"42","author":"Oakley","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1128\/AAC.42.2.282","article-title":"Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models","volume":"42","author":"Odds","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2011.08.006_bb0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/13693780802247702","article-title":"Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus","volume":"47","author":"Pasqualotto","year":"2009","journal-title":"Med. Mycol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0160","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European committee on antimicrobial susceptibility testing","volume":"53","author":"Perkhofer","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0165","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.diagmicrobio.2010.01.001","article-title":"Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods","volume":"67","author":"Pfaller","year":"2010","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0175","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JCM.02432-10","article-title":"Comparison of the broth microdilution methods of the European Committee on antimicrobial susceptibility testing and the clinical and laboratory standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus species","volume":"49","author":"Pfaller","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0180","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1128\/JCM.00535-08","article-title":"In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species","volume":"46","author":"Pfaller","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0185","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0190","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0195","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1128\/AAC.00597-10","article-title":"Comparison of caspofungin MICs by means of EUCAST method EDef 7.1 using two different concentrations of glucose","volume":"54","author":"Rodriguez-Tudela","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0200","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijantimicag.2008.05.015","article-title":"In vitro interaction of itraconazole and micafungin against clinically important filamentous fungi","volume":"32","author":"Ruiz-Cendoya","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0205","doi-asserted-by":"crossref","first-page":"e16086","DOI":"10.1371\/journal.pone.0016086","article-title":"High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites","volume":"6","author":"Rudramurthy","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0210","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0215","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1348-0421.1999.tb01231.x","article-title":"Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus","volume":"43","author":"Seo","year":"1999","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/j.1439-0507.2010.01996.x","article-title":"In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs","volume":"54","author":"Shivaprakash","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0225","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds","volume":"14","author":"Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0230","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drup.2009.09.002","article-title":"Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints","volume":"12","author":"Verweij","year":"2009","journal-title":"Drug. Res. Updates"},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0235","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMc061720","article-title":"Multiple-triazole-resistant aspergillosis","volume":"356","author":"Verweij","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dki399","article-title":"In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp","volume":"57","author":"Warn","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.08.006_bb0250","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2010.06.003","article-title":"In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan","volume":"36","author":"Yamazaki","year":"2010","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931100318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931100318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T08:44:47Z","timestamp":1592988287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288931100318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S073288931100318X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2011.08.006","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}